Abstract
Primary Liver Cancer (PLC) represents a high malignant tumor including HepatoCellular Carcinoma (HCC)1 Intrahepatic-Cholangio-Carcinoma (ICC)1. Although there has been suggestions for adjuvant chemotherapy for ICC vs. no systemic treatment for HCC after complete surgical resection the 5-year survival rate of resectable ICC is lower than 60% for HCC after surgery alone.
Revolutionizing biomedical research, NGS technologies provide new horizons in both prevention and treatment setting of PLC. Assessing cancer driver genes associated with environmental risk factors more effective progress can be developed.
In the treatment setting, revealing novel druggable mutations by NGS studies, not only new targeted drugs can be discovered but also robust biomarkers could potentially enhance precise targeting of individual patient’s comprehensive mutational landscape.
Primary Liver Cancer (PLC) remains poor due to resistance to available therapeutics. Multiple phase 3 randomized controlled trials (RCTs) evaluating the efficacy of targeted agents have failed, with the exception of regorafenib in patients with HCC who progressed on sorafenib2. Based on these limitations, emerging research is focused on cell origins, molecular classification and tumorigenesis3, as well as tumor heterogeneity, metastasis and therapeutic resistance1. The rapid progress and validity of next-generation sequencing (NGS) to identify genetic and genomic heterogeneity4, 5, as well as genome-wide mutational landscape, have contributed to our understanding of the molecular mechanisms that underlie therapeutic resistance and relapse. Strategic designs to discover novel oncotargets shape an early drug development concept6 for precision therapies bu targeting an individual patient’ genomic alterations (GAs)7, 8.

(Citation: Gastric & Breast Cancer 2017; 12(2): 67-72)

Back

PDF Version